• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)

December 17, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – 17 December 2021 – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 17, 2021 indicating that Tolefi SA and related persons have crossed together the statutory threshold of 20%, holding 18,65% of the voting rights of the company as of 8 December 2021.

Content of the Notification:

  • Reason of the Notification:

Downward passive crossing of the 20% threshold

Downward passive crossing by persons acting in concert

  • Notification by:

Persons acting in concert

  • Persons subject to the notification requirement:

Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle

Serge Goblet

Isabelle Thoumyre

Jérôme Goblet

Jean-Daniel Goblet

  • Transaction date

December 8, 2021

  • Threshold that is crossed (in %)

20

  • Denominator

24.961.981

  • Notified details:
A) Voting RightsPrevious notificationAfter the Transaction
 #of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to the securitiesNot linked to the securitiesLinked to the securitiesNot linked to the securities
Tolefi SA4.591.4024.591.402   18,39% 
Serge Goblet56.18056.180 0,23% 
Isabelle Thoumyre7.3007.300 0,03% 
Jérôme Goblet250250 0,00% 
Jean-Daniel Goblet384384 0,00% 
TOTAL4.655.5164.655.516 18,65% 

Tolefi SA is 100% controlled by Serge Goblet, Isabelle Thoumyre, Jérôme and Jean-Daniel Goblet.

Miscellaneous

  • The Press Release may be consulted on the website of Celyad Oncology via this link.

The notification can be consulted on the website if Celyad Oncology via this link.

  • Contact person(s):

By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use